Fresenius Kabi Expands US Sterile Injectables Capacity

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-09-07-2016
Volume 11
Issue 9

Fresenius Kabi will add to its generic, sterile injectable manufacturing at its Melrose Park, Illinois site.

Fresenius Kabi will invest approximately $250 million over 10 years to expand the company’s Melrose Park site, which manufactures generic, sterile injectable pharmaceuticals used in hospitals and clinics throughout the United States, the company announced on Aug. 17, 2016. The expansion of the current Melrose Park site (near Chicago, Illinois) into a manufacturing campus is a multi-stage, multi-year project with ground breaking planned for 2017 and final project completion in 2026.

“We are creating a state-of-the-art pharmaceutical manufacturing campus that will be a showcase for our company and the production of injectable generic medicines,” said Steven R. Nowicki, senior vice-president of Global Operations for North America, Pharmaceuticals Division at Fresenius Kabi. Fresenius Kabi operates more than 70 manufacturing sites across the globe, including other sites in Illinois as well as in New York, North Carolina, and Pennsylvania; the Melrose Park location will be one of its largest.

The plant today produces a broad range of generic injectable medicines used to treat critically and chronically ill patients.  The expansion will create multiple new buildings connected to the existing manufacturing site and will feature fully automated aseptic filling lines using state-of-the-art isolator technology, expanded lyophilization (freeze-drying) capabilities, formulation areas, a dedicated warehouse for raw materials and components, and an administration building. 

“Our goal is to expand our US manufacturing capabilities while ensuring continued compliance with increasing regulatory and quality requirements and improve production capacity and efficiency,” Nowicki added.

Source: Fresenius Kabi

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Related Content